Published in Cancer Biol Ther on January 01, 2014
TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. BMC Cancer (2015) 0.82
Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther (2015) 0.80
The structure of the death receptor 4-TNF-related apoptosis-inducing ligand (DR4-TRAIL) complex. Acta Crystallogr F Struct Biol Commun (2015) 0.78
Mining for Candidate Genes Related to Pancreatic Cancer Using Protein-Protein Interactions and a Shortest Path Approach. Biomed Res Int (2015) 0.77
LPS promotes resistance to TRAIL-induced apoptosis in pancreatic cancer. Infect Agent Cancer (2017) 0.75
A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods (1991) 16.64
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 3.88
Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ (2003) 3.66
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther (2005) 3.27
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity (2000) 2.99
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 2.87
TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol (2000) 2.80
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res (2009) 2.09
Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res (2008) 1.88
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2004) 1.88
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene (2000) 1.69
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ (2004) 1.62
Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res (2008) 1.53
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol (2006) 1.52
Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res (2000) 1.51
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol (2001) 1.46
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A (2006) 1.45
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther (2006) 1.45
Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res (2009) 1.42
Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells (2009) 1.40
Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene (2006) 1.37
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry (2000) 1.34
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34
Following a TRAIL: update on a ligand and its five receptors. Cell Res (2004) 1.33
TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res (2005) 1.29
Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene (2001) 1.22
Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res (2006) 1.18
2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity (1999) 1.14
Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med (2008) 1.13
Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol Med (2002) 1.12
TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res (2010) 1.08
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis (2010) 1.06
Random mutagenesis by error-prone PCR. Methods Mol Biol (2010) 1.04
Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther (2006) 1.03
TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2. J Invest Dermatol (2003) 1.03
DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem (2008) 1.01
TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J Mol Med (Berl) (2010) 0.99
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res (2009) 0.99
Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells (2010) 0.99
TRAIL/TRAIL-R in hematologic malignancies. J Cell Biochem (2010) 0.97
RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies. Adv Exp Med Biol (2009) 0.96
MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release. Oncogene (2007) 0.91
Unraveling the binding mechanism of trivalent tumor necrosis factor ligands and their receptors. Mol Cell Proteomics (2010) 0.90
Modulation of TRAIL signaling for cancer therapy. Vitam Horm (2004) 0.90
AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Ther (2004) 0.90
The secretable form of trimeric TRAIL, a potent inducer of apoptosis. Biochem Biophys Res Commun (2004) 0.90
Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry (2009) 0.90
Targeting AML through DR4 with a novel variant of rhTRAIL. J Cell Mol Med (2011) 0.89
Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer (2011) 0.87
Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects. Cell Death Dis (2013) 0.86
Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL. Mol Cell Proteomics (2012) 0.85
NF-kappaB kinetics predetermine TNF-alpha sensitivity of colorectal cancer cells. J Gene Med (2001) 0.83
Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis. Cancer Cell Int (2011) 0.81
IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells. Cancer Lett (2011) 0.80
Proteomics of protein secretion by Bacillus subtilis: separating the "secrets" of the secretome. Microbiol Mol Biol Rev (2004) 2.67
The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol Mol Biol Rev (2012) 2.36
Bacillus subtilis as cell factory for pharmaceutical proteins: a biotechnological approach to optimize the host organism. Biochim Biophys Acta (2004) 1.80
Quorum quenching by an N-acyl-homoserine lactone acylase from Pseudomonas aeruginosa PAO1. Infect Immun (2006) 1.77
Genome engineering reveals large dispensable regions in Bacillus subtilis. Mol Biol Evol (2003) 1.55
Immunomodulation by n-3- versus n-6-rich lipid emulsions in murine acute lung injury--role of platelet-activating factor receptor. Crit Care Med (2007) 1.52
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A (2006) 1.45
A non-apoptotic role for caspase-9 in muscle differentiation. J Cell Sci (2008) 1.42
The bdbDC operon of Bacillus subtilis encodes thiol-disulfide oxidoreductases required for competence development. J Biol Chem (2001) 1.38
Thiol-disulfide oxidoreductases are essential for the production of the lantibiotic sublancin 168. J Biol Chem (2002) 1.38
Selective contribution of the twin-arginine translocation pathway to protein secretion in Bacillus subtilis. J Biol Chem (2002) 1.32
Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells. Mol Cell Biol (2005) 1.26
Thiol-disulphide oxidoreductase modules in the low-GC Gram-positive bacteria. Mol Microbiol (2007) 1.26
Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res (2006) 1.18
Role of PvdQ in Pseudomonas aeruginosa virulence under iron-limiting conditions. Microbiology (2009) 1.09
TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res (2010) 1.08
Quorum-quenching acylase reduces the virulence of Pseudomonas aeruginosa in a Caenorhabditis elegans infection model. Antimicrob Agents Chemother (2009) 1.03
The quorum-quenching N-acyl homoserine lactone acylase PvdQ is an Ntn-hydrolase with an unusual substrate-binding pocket. Proc Natl Acad Sci U S A (2009) 1.02
Directed evolution: selecting today's biocatalysts. Biomol Eng (2005) 1.02
DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem (2008) 1.01
The CssRS two-component regulatory system controls a general secretion stress response in Bacillus subtilis. FEBS J (2006) 1.00
Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells (2010) 0.99
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res (2009) 0.99
Functional analysis of genes involved in the biosynthesis of isoprene in Bacillus subtilis. Appl Microbiol Biotechnol (2007) 0.98
Genes involved in SkfA killing factor production protect a Bacillus subtilis lipase against proteolysis. Appl Environ Microbiol (2005) 0.98
Functional genomic analysis of the Bacillus subtilis Tat pathway for protein secretion. J Biotechnol (2002) 0.97
Proteomic dissection of potential signal recognition particle dependence in protein secretion by Bacillus subtilis. Proteomics (2006) 0.96
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther (2011) 0.96
Both human and mouse mesenchymal stem cells promote breast cancer metastasis. Stem Cell Res (2011) 0.96
PA0305 of Pseudomonas aeruginosa is a quorum quenching acylhomoserine lactone acylase belonging to the Ntn hydrolase superfamily. Microbiology (2011) 0.95
Secretion of functional human interleukin-3 from Bacillus subtilis. J Biotechnol (2005) 0.94
Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. J Cell Sci (2012) 0.92
A disulfide bond-containing alkaline phosphatase triggers a BdbC-dependent secretion stress response in Bacillus subtilis. Appl Environ Microbiol (2006) 0.92
FlhF, the third signal recognition particle-GTPase of Bacillus subtilis, is dispensable for protein secretion. J Bacteriol (2004) 0.92
RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res (2005) 0.92
Binding of phage displayed Bacillus subtilis lipase A to a phosphonate suicide inhibitor. J Biotechnol (2003) 0.91
Combinatorial biosynthesis of medicinal plant secondary metabolites. Biomol Eng (2006) 0.91
Extracellular lipases from Bacillus subtilis: regulation of gene expression and enzyme activity by amino acid supply and external pH. FEMS Microbiol Lett (2003) 0.91
Unraveling the binding mechanism of trivalent tumor necrosis factor ligands and their receptors. Mol Cell Proteomics (2010) 0.90
Alteration of the diastereoselectivity of 3-methylaspartate ammonia lyase by using structure-based mutagenesis. Chembiochem (2009) 0.90
Modulation of thiol-disulfide oxidoreductases for increased production of disulfide-bond-containing proteins in Bacillus subtilis. Appl Environ Microbiol (2008) 0.90
Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry (2009) 0.90
Signal peptide hydrophobicity is critical for early stages in protein export by Bacillus subtilis. FEBS J (2005) 0.90
Reactive oxygen species modulate HIF-1 mediated PAI-1 expression: involvement of the GTPase Rac1. Thromb Haemost (2003) 0.89
Targeting AML through DR4 with a novel variant of rhTRAIL. J Cell Mol Med (2011) 0.89
Altering the substrate specificity of cephalosporin acylase by directed evolution of the Beta -subunit. J Biol Chem (2002) 0.89
Production of α-cuprenene in Xanthophyllomyces dendrorhous: a step closer to a potent terpene biofactory. Microb Cell Fact (2013) 0.87
Genetic or chemical protease inhibition causes significant changes in the Bacillus subtilis exoproteome. Proteomics (2008) 0.86
Mutational analysis of a key residue in the substrate specificity of a cephalosporin acylase. Chembiochem (2004) 0.86
Engineering methylaspartate ammonia lyase for the asymmetric synthesis of unnatural amino acids. Nat Chem (2012) 0.86
Improved beta-lactam acylases and their use as industrial biocatalysts. Curr Opin Biotechnol (2004) 0.86
The conformation of the extracellular binding domain of Death Receptor 5 in the presence and absence of the activating ligand TRAIL: a molecular dynamics study. Proteins (2008) 0.85
Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL. Mol Cell Proteomics (2012) 0.85
In situ trapping of initiator caspases reveals intermediate surprises. Cell Biol Int (2006) 0.85
Bridging between organocatalysis and biocatalysis: asymmetric addition of acetaldehyde to β-nitrostyrenes catalyzed by a promiscuous proline-based tautomerase. Angew Chem Int Ed Engl (2011) 0.84
Lipase expression in Pseudomonas alcaligenes is under the control of a two-component regulatory system. Appl Environ Microbiol (2008) 0.84
Characterization of a newly identified mycobacterial tautomerase with promiscuous dehalogenase and hydratase activities reveals a functional link to a recently diverged cis-3-chloroacrylic acid dehalogenase. Biochemistry (2011) 0.84
Heterologous production of Escherichia coli penicillin G acylase in Pseudomonas aeruginosa. J Biotechnol (2009) 0.84
Stabilization of TRAIL, an all-beta-sheet multimeric protein, using computational redesign. Protein Eng Des Sel (2004) 0.84
Reducing virulence of the human pathogen Burkholderia by altering the substrate specificity of the quorum-quenching acylase PvdQ. Proc Natl Acad Sci U S A (2014) 0.84
Caenorhabditis elegans reveals novel Pseudomonas aeruginosa virulence mechanism. Trends Microbiol (2013) 0.83
Selection strategies for improved biocatalysts. FEBS J (2007) 0.83
Phage display of an intracellular carboxylesterase of Bacillus subtilis: comparison of Sec and Tat pathway export capabilities. Appl Environ Microbiol (2006) 0.83
Characterization of Saccharomyces cerevisiae Ras1p and chimaeric constructs of Ras proteins reveals the hypervariable region and farnesylation as critical elements in the adenylyl cyclase signaling pathway. Biochemistry (2003) 0.83
Enhancement of the promiscuous aldolase and dehydration activities of 4-oxalocrotonate tautomerase by protein engineering. Chembiochem (2012) 0.82
Systematic screening for catalytic promiscuity in 4-oxalocrotonate tautomerase: enamine formation and aldolase activity. Chembiochem (2011) 0.82
Kinetic resolution and stereoselective synthesis of 3-substituted aspartic acids by using engineered methylaspartate ammonia lyases. Chemistry (2013) 0.82
Antibody-free LC-MS/MS quantification of rhTRAIL in human and mouse serum. Anal Chem (2013) 0.82
The molecular cloning of dihydroartemisinic aldehyde reductase and its implication in artemisinin biosynthesis in Artemisia annua. Planta Med (2010) 0.82
Detection of porcine circovirus 2 (PCV-2) DNA by nested PCR from formalin-fixed tissues of post-weaning multisystemic wasting syndrome (PMWS) pigs in Thailand. J Vet Med Sci (2002) 0.82
Directed evolution of Bacillus subtilis lipase A by use of enantiomeric phosphonate inhibitors: crystal structures and phage display selection. Chembiochem (2006) 0.82
Lignans from cell suspension cultures of Phyllanthus niruri, an Indonesian medicinal plant. J Nat Prod (2006) 0.82
The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells. Oncol Rep (2009) 0.81
Characterization of a thermostable methylaspartate ammonia lyase from Carboxydothermus hydrogenoformans. Appl Microbiol Biotechnol (2011) 0.81
Mucosal protection by phosphatidylcholine. Dig Dis (2013) 0.81
Seasonal variations in the deoxypodophyllotoxin content and yield of Anthriscus sylvestris L. (Hoffm.) grown in the field and under controlled conditions. J Agric Food Chem (2011) 0.81
Directed evolution of a glutaryl acylase into an adipyl acylase. Eur J Biochem (2002) 0.81
RGD-avidin-biotin pretargeting to alpha v beta 3 integrin enhances the proapoptotic activity of TNF alpha related apoptosis inducing ligand (TRAIL). Apoptosis (2008) 0.81
Analysis of a substrate specificity switch residue of cephalosporin acylase. Biochem Biophys Res Commun (2003) 0.81
A phytochemical study of lignans in whole plants and cell suspension cultures of Anthriscus sylvestris. Planta Med (2003) 0.80
IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells. Cancer Lett (2011) 0.80